Mineralys Therapeutics to Participate in Upcoming Investor Conferences
![GlobeNewswire](../../../Content/images/providers/GN.png)
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: GlobeNewswire
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation Conference:Date:Tuesday, November 12, 2024Time:4:00pm ESTFormat:Fireside ChatWebcast Link Stifel Healthcare Conference:Date:Tuesday, November 19, 2024Time:10:20am ESTFormat:Fireside ChatWebcast Link Evercore ISI HealthCONx ConferenceDate:Wednesday, December 4, 2024Time:4:15pm ESTFormat:Fireside ChatWebcast Link Live webcasts of the fireside chats can be accessed under “
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $28.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Mineralys Therapeutics reports Q4 results [Seeking Alpha]Seeking Alpha
- Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025GlobeNewswire
MLYS
Earnings
- 2/12/25 - Beat
MLYS
Sec Filings
- 2/14/25 - Form S-8
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form 4
- MLYS's page on the SEC website